Recent clinical trials have demonstrated that neoadjuvant administration of PD-1 + /- CTLA-4 inhibitor is superior to adjuvant PD-1 inhibitors in patients with resectable stage III and IV cutaneous melanoma.
However, the generalizability of these results to an unselected patient population treated in routine clinical settings remains unclear.
